Business Wire

Novaremed announces that it has raised CHF 6 million to prepare for a Phase 2b clinical study in Diabetic Neuropathic Pain

Del

Novaremed AG, a Swiss clinical-stage biopharmaceutical company, announced today that it has successfully raised additional financing of CHF 6 million from existing shareholders and several new private investors. The financing raised via a rights offering, with pro-rata rights for existing shareholders, was significantly oversubscribed. The proceeds of the financing will be used to prepare for a global Phase 2b clinical study of its lead compound, NRD.E1, a novel, first-in-class, small molecule for patients suffering from diabetic neuropathic pain (DNP).

Eli Kaplan, MD, Founder and CEO of Novaremed AG, commented: “I am delighted that our existing shareholders and several new private investors invested significantly in our rights offering. Their investment commitment reflects the potential they see in Novaremed and its lead program in DNP.”

Together with CHF 4.44 million raised in April 2018, the company will be well capitalized to prepare for a global Phase 2b clinical study, which is expected to be initiated in H2 2019.

Notes to the Editor:

About diabetic neuropathic pain (DNP)

Diabetes (Type 1 and Type 2) is the leading cause for neuropathy.1 Up to 20% of diabetic patients suffers from DNP2 and two-third of those – more than 15 million patients - experience chronic, debilitating pain that substantially impairs quality of life. The efficacy of available treatments is limited and associated with many adverse effects and drug to drug interactions.

1. Snyder, MJ; Gibbs, LM; Lindsay, TJ: “Treating Painful Diabetic Peripheral Neuropathy: An Update”. American Family Physician. 94 (3): 227–34, 2016

2. van Hecke O. Et al; Pain 2014, 155: 654-662

About NRD.E1

NRD.E1 is a small, once daily, orally available molecule, first synthesized in 2009. NRD.E1 has been shown to be an allosteric modulator of Lyn Kinase and is first in class. It is currently being developed for the treatment of DNP. The recently concluded 3-week, placebo-controlled, randomized Phase 2a proof of concept clinical study in 88 patients suffering from DNP showed clinically relevant reduction in patient-reported pain. NRD.E1 was well tolerated at all doses studied on the Phase 2a study.

About Novaremed

Novaremed Ltd. was founded in 2008 in Israel. In early 2018, the clinical-stage biopharmaceutical company was incorporated in Switzerland as Novaremed AG to gain rapid access to highly qualified staff and services required for rapid clinical development on a global scale. Besides evaluation of its lead compound NRD.E1 in DNP, further indications will be explored as part of a comprehensive life-cycle management, supported by efficacy demonstrated in multiple animal models of pain and other indications.

Contact information

Novaremed AG
Subhasis Roy, Chief Operating Officer
Tel: +41 79 2075715
Email: subhasis.roy@novaremed.com
Web: www.novaremed.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Prominent Coalition of World Class International and Danish Law Firms and ISAF Management Company Proceed with Investor Lawsuit against Danske Bank20.11.2018 23:00Pressemelding

International Securities Associations and Foundations Management Company (“ISAF”) announces the formation of an international coalition of leading American, German and Dutch law firms and the appointment of the preeminent Danish law firm, Németh Sigetty, to proceed with a lawsuit against Danske Bank A/S (“Danske” or the “Bank”) to pursue compensation for damaged investors after revelations of money laundering, financial mismanagement and deficient regulatory disclosures. The lawsuit will be filed in Copenhagen, Denmark on behalf of investors who suffered investment losses in Danske’s share price after various disclosures related to an estimated EUR €200 billion money transfer scheme involving non-resident Eastern European and Russian customers in the Bank’s Estonian Branch. Information about critical lapses in Danske’s ‘know your customer’ and anti-money laundering internal enforcement policies, and its failure to act upon both internal and external warnings of non-compliance, caused a

Saif bin Zayed Witnesses Endorsement of Abu Dhabi Declaration by Religious Leaders at Wahat Al Karama20.11.2018 22:28Pressemelding

Under the patronage of His Highness Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, Lt. General HH Sheikh Saif bin Zayed Al Nahyan, Deputy Prime Minister and Minister of Interior, attended the endorsement of the “Abu Dhabi Declaration.” The declaration, issued by the Interfaith Alliance for Safer Communities: Child Dignity in the Digital World Forum was endorsed and approved by religious and spiritual leaders participating in the two-day assembly, which took place in Abu Dhabi on November 19-20, who pledged to act upon the declaration’s articles and achieve the objectives and obligations outlined by the leaders of the seven major world religions participating in the forum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005775/en/ Saif bin Zayed, Khalifa bin Tahnoun, alongside religious and spiritual leaders in front of a memorial to express commitment

Guy Carpenter Names Ross Howard Vice Chairman20.11.2018 17:46Pressemelding

Guy Carpenter & Company, LLC, a leading global risk and reinsurance specialist and a wholly owned subsidiary of Marsh & McLennan Companies (NYSE: MMC), today announced a new leadership appointment from the Jardine Lloyd Thompson Group plc (JLT) reinsurance organization. Effective upon closing of the transaction between Guy Carpenter’s parent company, Marsh & McLennan Companies and JLT, which remains subject to the receipt of certain antitrust and financial regulatory approvals, Ross Howard, Chairman of JLT Re, will become Vice Chairman of Guy Carpenter, reporting to President & CEO Peter Hearn. Mr. Howard will also become a member of Guy Carpenter’s Executive Committee and will be responsible for developing new business opportunities and assisting with client relationships in order to continue the growth of the combined global reinsurance business. Additionally, Mr. Howard will also play a key role in executing the integration of JLT Re with Guy Carpenter. “We are very excited to take

IDEMIA Will Present Its 2018 Quarterly Financial Results to Investors on November 21, 201820.11.2018 17:31Pressemelding

IDEMIA, the world leader in Augmented Identity, today announced that it will present its Q3 2018 financial results to investors on Wednesday November 21, 2018. Yann Delabrière (CEO), Frédéric Beylier (COO) and Laurent Lemaire (CFO) will be presenting the financial results and taking questions the same day at 1:00 pm CET (12:00 pm London Time / 7:00 am New York Time). For more information, please refer to our website: http://investors.oberthur.com About IDEMIA OT-Morpho is now IDEMIA, the global leader in Augmented Identity, with the ambition to empower citizens and consumers alike to interact, pay, connect, travel and vote in ways that are now possible in a connected environment. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable t

OCP Announces Date of Third Quarter 2018 Earnings20.11.2018 17:00Pressemelding

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter 2018 results on Thursday, November 29, 2018. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 8:30 a.m. EST, 2:30 p.m. Morocco time (GMT+1), and 1:30 p.m. London time (GMT). OCP senior management will host a conference call to discuss third quarter 2018 results at 9:30 a.m. EST, 3:30 p.m. Morocco time (GMT+1), and 2:30 p.m. London time (GMT) on Thursday, November 29, 2018 for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. O

Arch Insurance Announces Strategic Leadership Changes20.11.2018 15:50Pressemelding

Arch Insurance (“Arch”) today announced Hugh Sturgess will assume the role of Chief Executive Officer, Arch Insurance International, effective Jan. 1, 2019, subject to regulatory approvals. Arch Insurance International includes Arch’s insurance operations in Europe, Bermuda and Australia. Mr. Sturgess has been with Arch Insurance since 2005 and is currently President and CEO of Arch Insurance Canada Ltd., where he has strategic and operational responsibility for a multi-line underwriting portfolio. Before joining Arch, Mr. Sturgess held various roles in the financial services industry, including tenures with the Royal Bank of Canada and Chubb Insurance Company of Canada. “Arch Insurance International underwrites a diverse portfolio of specialty insurance solutions across a number of geographies, with a key focus on providing value to our distribution partners and customers,” Mr. Sturgess said. “I look forward to the opportunity to work with our team in continuing to expand the value pr